Corvus Pharmaceuticals (CRVS) Gains from Investment Securities (2022 - 2025)
Historic Gains from Investment Securities for Corvus Pharmaceuticals (CRVS) over the last 4 years, with Q2 2025 value amounting to -$2.0 million.
- Corvus Pharmaceuticals' Gains from Investment Securities fell 48323.81% to -$2.0 million in Q2 2025 from the same period last year, while for Sep 2025 it was -$24.8 million, marking a year-over-year decrease of 18116.14%. This contributed to the annual value of $33.4 million for FY2024, which is 322518.73% up from last year.
- According to the latest figures from Q2 2025, Corvus Pharmaceuticals' Gains from Investment Securities is -$2.0 million, which was down 48323.81% from -$25.1 million recorded in Q1 2025.
- In the past 5 years, Corvus Pharmaceuticals' Gains from Investment Securities registered a high of $32.8 million during Q3 2024, and its lowest value of -$25.1 million during Q1 2025.
- Over the past 4 years, Corvus Pharmaceuticals' median Gains from Investment Securities value was $588860.0 (recorded in 2022), while the average stood at $808821.8.
- As far as peak fluctuations go, Corvus Pharmaceuticals' Gains from Investment Securities surged by 32830.74% in 2024, and later plummeted by 874823.94% in 2025.
- Quarter analysis of 4 years shows Corvus Pharmaceuticals' Gains from Investment Securities stood at -$985000.0 in 2022, then fell by 4.37% to -$1.0 million in 2023, then soared by 328.31% to $2.3 million in 2024, then tumbled by 185.73% to -$2.0 million in 2025.
- Its Gains from Investment Securities was -$2.0 million in Q2 2025, compared to -$25.1 million in Q1 2025 and $2.3 million in Q4 2024.